The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

The grant will fund the development of a novel formulation of SNX631-6, the Company's CDK8/19 Mediator kinase inhibitor and clinical candidate as a treatment for metastatic ovarian cancer (OC).

Researchers at Johns Hopkins and the Chinese Academy of Sciences discovered that a mouse protein, STELLA, blocks the ...